



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

~~TRADE SHOW~~ Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 1 of 2

Digitized by srujanika@gmail.com

FOREIGN PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear
		Country Code ³ - Number ⁴ - Kind Code ⁵ (if known)	MM-DD-YYYY		
		WO 03/016475 A2	02-27-2003	Bayer Ag	
		WO 01/62920 A2	08-30-2001	Curagen Corp	
		WO 02/08288 A3	01-31-2002	Genentech, Inc	
		WO 02/22802 A1	03-21-2002	Schering-Plough Beecham	
		WO 84/03504	12-09-1985	GRP Genie Genetique	
		WO 01/21651 A2	03-29-2001	Lexicon Genetics, Inc	

Examiner Signature	/Anand Desai/	Date Considered	06/30/2008
--------------------	---------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 801.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: **Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet

2

of

2

Complete if Known

Application Number	10/551,176
Filing Date	September 30, 2005
First Named Inventor	ONICHTCHOUK, Daria
Art Unit	TBD 1656
Examiner Name	TBD /Anand Desai/
Attorney Docket Number	8054-005-US

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
/A.D./		BRUNING et al., Mol. Cell. 2:449-569 (1998).	
		KATAYAMA, S. et al., Science, 309(5740):1564-1566(2005).	
		WATSON, J.E. et al., Oncogene, 23(19)3487-3494 (2004).	
		SORA, I. et al., PNAS, 96:7752-7755 (1999).	
		Genbank Accession No. NP_084485, Mus Musculus RIKEN cDNA 1810049K24 gene (1810049K24Rik). Retrieved Dec. 20, 2005.	
		Genbank Accession No. NM_030209, Mus Musculus RIKEN cDNA 1810049K24 gene (1810049K24Rik). Retrieved January 9, 2006.	
		Genbank Accession No. NM_031476, Homo sapiens hypothetical protein DKFZP434B044(DKFZp434B044) Retrieved January 9, 2006.	
		Genbank Accession No. NP_113664, Homo sapiens hypothetical protein DKFZP434B044(DKFZp434B044). Retrieved Dec. 20, 2005.	
↓		Accession No. Q9H0B8, Hypothetical protein DKFZp43B044 (March 1, 2001), retrieved from Database Uniprot EMBL/EBI at www.EMBL/EBI.AC.UK	

Examiner Signature	/Anand Desai/	Date Considered	06/30/2008
--------------------	---------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.